Evaluation of the use of intranasal atipamezole to reverse the sedative effects of xylazine in dogs
Alex P. Focken, Jordan M. Woodsworth, Jennifer M. Loewen- General Veterinary
Abstract
Objective
To assess the ability of intranasal atipamezole to reverse sedative effects of xylazine in dogs.
Design
Prospective proof‐of‐concept study.
Setting
University research laboratory.
Animal
Six healthy, staff‐owned dogs.
Interventions
Dogs were sedated with 1.1 mg/kg of xylazine intravenously. The sedation score of each dog was recorded every 5 minutes until they achieved a sedation score of >13/21 for 3 readings. Once achieved, 0.3 mg/kg of atipamezole was administered intranasally using a mucosal atomization device. Sedation scores continued to be recorded every 5 minutes until successful reversal was achieved (<4/21).
Measurements and Main Results
Average times to standing and normal wakefulness after administration of intranasal atipamezole were 6 minutes, 30 seconds and 7 minutes, 20 seconds, respectively.
Conclusions
Intranasal atipamezole successfully reversed the sedation effects of xylazine. The findings of this study provide justification for future controlled prospective studies into the potential use of intranasal atipamezole in a variety of settings including exposure to xylazine in operational canines as well as bioavailability studies for optimal dosing.